« Return to News | R&D Trends | Drug Sponsors

North American pharma growing by overseas acquisitions

Tuesday, May 31, 2011 03:24 PM

European drugmakers have more competition for nearby buyouts these days, according to a report on FiercePharma. With North America's pharma companies turning to international markets for growth, they're scouting Central Europe, Eastern Europe, Turkey and the Middle East for potential generics deals, which is likely to push prices upward, experts told Dow Jones.

Most recent Central European pharma deals went to a European drugmaker or an Indian company, according to investment bankers. Now, North American companies are making acquisitions, such as Canadian drugmaker Valeant Pharmaceuticals' buyout of Lithuania's AB Sanitas and U.S.-based Watson Pharmaceuticals' purchase of Greece's Specifar.

Dow Jones said not only were the winning bidders in these deals North American, but the entire bidding pool was dominated by North American companies. That trend hasn't gone unnoticed in the M&A community; UBS has identified 17 pharma companies in "local" emerging markets that could be acquisition targets, including Hungary's Gedeon Richter and Hikma Pharmaceuticals of Jordan.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.